De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course

Ramachandran, Preethi; Sahni, Sonu; Wang, Jen C.

doi:10.1177/2324709619893546

Cited by 2 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with CD5− DLBCL, there is inferior overall survival in CD5+ DLBCL ( P = 0.0352). Yamaguchi et al 16,17 also reached the same conclusion in the previous article. Currently, it has not been adequately explored the underlying mechanisms of poor prognosis in CD5+ DLBCL; summary of the predecessors reported; CD5 alters the tumor immune microenvironment to achieve the proliferation load of tumor cells by modulating multiple signal cascades, including BCR-dependent and non-dependent pathways.…”

Section: Discussionsupporting

confidence: 78%

Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma

Yang

Niu

Yang

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

CD5+ diffuse large B-cell lymphoma (DLBCL), as a significant heterogeneity category of DLBCL, is reflected in both the molecular biological and genetic levels, which in turn induces ever-changing clinical manifestations, and what mediates tumor survival mechanisms are still unclear. This study aimed to predict the potential hub genes in CD5+ DLBCL. A total of 622 patients with DLBCL diagnosed between 2005 and 2019 were included. High expression of CD5 was correlated with IPI, LDH, and Ann Arbor stage, patients with CD5-DLBCL have longer overall survival. We identified 976 DEGs between CD5-negative and positive DLBCL patients in the GEO database and performed GO and KEGG enrichment analysis. After intersecting the genes obtained through the Cytohubba and MCODE, further external verification was performed in the TCGA database. Three hub genes were screened: VSTM2B, GRIA3, and CCND2, of which CCND2 were mainly involved in cell cycle regulation and JAK-STAT signaling pathways. Analysis of clinical samples showed that the expression of CCND2 was found to be correlated with CD5 ( p = 0.001), and patients with overexpression of CCND2 in CD5+ DLBCL had poor prognosis ( p = 0.0455). Cox risk regression analysis showed that, for DLBCL, CD5, and CCND2 double positive was an independent poor prognostic factor (HR: 2.545; 95% CI: 1.072–6.043; p = 0.034). These findings demonstrate that CD5 and CCND2 double-positive tumors should be stratified into specific subgroups of DLBCL with poor prognosis. CD5 may regulate CCND2 through JAK-STAT signaling pathways, mediating tumor survival. This study provides independent adverse prognostic factors for risk assessment and treatment strategies for newly diagnosed DLBCL.

show abstract

Section: Discussionsupporting

confidence: 78%

Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma

Yang

Niu

Yang

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

show abstract

“… 1 And diffuse large B‐cell lymphoma is the most commonly occurring type in the gastrointestinal tract. 2 The most frequently affected site of primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) is the stomach, followed by the small intestine and ileocecal region. 3 , 4 To date, there is still no consensus on its optimal regimens.…”

Section: Introductionmentioning

confidence: 99%

“…In the modern era, primary gastrointestinal lymphoma comprises about 30%–40% of cases in primary extranodal lymphomas 1 . And diffuse large B‐cell lymphoma is the most commonly occurring type in the gastrointestinal tract 2 . The most frequently affected site of primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) is the stomach, followed by the small intestine and ileocecal region 3,4 .…”

Section: Introductionmentioning

confidence: 99%

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score

et al. 2023

View full text Add to dashboard Cite

Background This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. Methods This retrospective analysis included 153 PGI‐DCBCL patients diagnosed between 2011 and 2021. These patients were divided into a training set ( n = 102) and a validation set ( n = 51). Univariate and multivariate Cox regression analyses were conducted to examine the significance of variables on overall survival (OS) and progression‐free survival (PFS). An inflammation‐covered score system was established according to the multivariate results. Results The presence of high pretreatment SIRI (≥1.34, p < 0.001) was significantly associated with poorer survival and identified as an independent prognostic factor. Compared with NCCN‐IPI, the prognostic and discriminatory capability of the novel model SIRI‐PI showed a more precise high‐risk assessment with a higher area under the curve (AUC) (0.916 vs 0.835) and C ‐index (0.912 vs 0.836) for OS in the training cohort, and similar results were obtained in the validation cohort. Moreover, SIRI‐PI also showed good discriminative power for efficacy assessment. This new model identified patients at risk of developing severe gastrointestinal complications following chemotherapy. Conclusions The results of this analysis suggested that the pretreatment SIRI may be a potential candidate for identifying patients with a poor prognosis. And we established and validated a better‐performing clinical model, which facilitated the prognostic stratification of PGI‐DLBCL patients and can serve as a reference for clinical decision‐making.

show abstract

De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course

Cited by 2 publications

References 23 publications

Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma

Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma

Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score

Contact Info

Product

Resources

About